Elisabeth Manville
Jan 27, 2012

Scientists discover, patent new cancer vaccine

Scientists at Trinity College Dublin in Ireland have published an article about their discovery of a new cancer vaccine approach. The therapeutic vaccine would manipulate immune responses to cancerous tumors. The discovery has been patented and there are plans to move on to the clinical stage.This new vaccine could have the potential to overcome the challenges faced by previous cancer vaccine attempts, including Sipuleucel-T, sold as Provenge, which was approved by the FDA in 2010 for the treatment of prostate cancer and extends life just over four months on average. The developers of this new vaccine hope to be more successful and improve on the existing techniques by preventing cancer cells from blocking the immune response that could kill them. In the pre-clinical stage the vaccine has shown the potential to be effective in treating a range of cancers.